-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, August 9 News On August 5, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's ibandronate sodium injection was approved as a supplementary application and became the second company to have reviewed the product
.
According to data from Menet.
com, the sales of terminal ibandronate sodium injection in public medical institutions in China have grown rapidly in recent years, and it will be close to 1 billion yuan in 2020.
Among them, Hebei Medical University has the largest market share of biology, exceeding 30%, and Chengdu Yuandong Biotechnology Pharmaceuticals followed closely behind, ranking second
.
.
According to data from Menet.
com, the sales of terminal ibandronate sodium injection in public medical institutions in China have grown rapidly in recent years, and it will be close to 1 billion yuan in 2020.
Among them, Hebei Medical University has the largest market share of biology, exceeding 30%, and Chengdu Yuandong Biotechnology Pharmaceuticals followed closely behind, ranking second
.
On August 5, 2021, the information of drug approval documents to be collected is released
Statistics show that ibandronate is injection as early as June 1996, the EU approved by the third-generation bisphosphonate Swiss pharmaceutical company Roche developed for the treatment of malignant tumor hypercalcemia, prevention Bone-related events in patients with breast cancer bone metastases (pathological fractures, bone complications requiring radiotherapy or surgery)
.
.
Sales of terminal ibandronate sodium injection in public medical institutions in China in recent years (unit: 100 million yuan)
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, in recent years , the sales of terminal ibandronate sodium injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly.
In 2020, it will be close to 1 billion yuan.
Among them, Hebei Medical University has the largest market share of biology, exceeding 30%, followed by Chengdu Yuandong Biopharmaceutical, ranking second
.
com, in recent years , the sales of terminal ibandronate sodium injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly.
In 2020, it will be close to 1 billion yuan.
Among them, Hebei Medical University has the largest market share of biology, exceeding 30%, followed by Chengdu Yuandong Biopharmaceutical, ranking second
.
Status of Supplementary Application for Consistency Evaluation of Ibandronate Sodium Injection
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Ibandronate sodium injection production companies include Chengdu Yuandong Biopharmaceuticals, Qilu Pharmaceuticals, Tianjin Hongri Pharmaceuticals, and Sichuan Meida Kangjiale Pharmaceuticals
.
In March of this year, Chengdu Yuandong Biopharmaceutical won the first review of ibandronate sodium injection.
This time, Qilu Pharmaceutical was approved and became the second company to review the product
.
At present, Ibandronate Sodium Injection and the supplementary application for consistency evaluation of Nanjing Hengsheng Pharmaceutical are under review and approval
.
.
In March of this year, Chengdu Yuandong Biopharmaceutical won the first review of ibandronate sodium injection.
This time, Qilu Pharmaceutical was approved and became the second company to review the product
.
At present, Ibandronate Sodium Injection and the supplementary application for consistency evaluation of Nanjing Hengsheng Pharmaceutical are under review and approval
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Medical Network, August 9 News On August 5, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's ibandronate sodium injection was approved as a supplementary application and became the second company to have reviewed the product
.
According to data from Menet.
com, the sales of terminal ibandronate sodium injection in public medical institutions in China have grown rapidly in recent years, and it will be close to 1 billion yuan in 2020.
Among them, Hebei Medical University has the largest market share of biology, exceeding 30%, and Chengdu Yuandong Biotechnology Pharmaceuticals followed closely behind, ranking second
.
.
According to data from Menet.
com, the sales of terminal ibandronate sodium injection in public medical institutions in China have grown rapidly in recent years, and it will be close to 1 billion yuan in 2020.
Among them, Hebei Medical University has the largest market share of biology, exceeding 30%, and Chengdu Yuandong Biotechnology Pharmaceuticals followed closely behind, ranking second
.
On August 5, 2021, the information of drug approval documents to be collected is released
Statistics show that ibandronate is injection as early as June 1996, the EU approved by the third-generation bisphosphonate Swiss pharmaceutical company Roche developed for the treatment of malignant tumor hypercalcemia, prevention Bone-related events in patients with breast cancer bone metastases (pathological fractures, bone complications requiring radiotherapy or surgery)
.
.
Sales of terminal ibandronate sodium injection in public medical institutions in China in recent years (unit: 100 million yuan)
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, in recent years , the sales of terminal ibandronate sodium injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly.
In 2020, it will be close to 1 billion yuan.
Among them, Hebei Medical University has the largest market share of biology, exceeding 30%, followed by Chengdu Yuandong Biopharmaceutical, ranking second
.
com, in recent years , the sales of terminal ibandronate sodium injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly.
In 2020, it will be close to 1 billion yuan.
Among them, Hebei Medical University has the largest market share of biology, exceeding 30%, followed by Chengdu Yuandong Biopharmaceutical, ranking second
.
Status of Supplementary Application for Consistency Evaluation of Ibandronate Sodium Injection
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Ibandronate sodium injection production companies include Chengdu Yuandong Biopharmaceuticals, Qilu Pharmaceuticals, Tianjin Hongri Pharmaceuticals, and Sichuan Meida Kangjiale Pharmaceuticals
.
In March of this year, Chengdu Yuandong Biopharmaceutical won the first review of ibandronate sodium injection.
This time, Qilu Pharmaceutical was approved and became the second company to review the product
.
At present, Ibandronate Sodium Injection and the supplementary application for consistency evaluation of Nanjing Hengsheng Pharmaceutical are under review and approval
.
.
In March of this year, Chengdu Yuandong Biopharmaceutical won the first review of ibandronate sodium injection.
This time, Qilu Pharmaceutical was approved and became the second company to review the product
.
At present, Ibandronate Sodium Injection and the supplementary application for consistency evaluation of Nanjing Hengsheng Pharmaceutical are under review and approval
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Medical Network, August 9 News On August 5, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's ibandronate sodium injection was approved as a supplementary application and became the second company to have reviewed the product
.
According to data from Menet.
com, the sales of terminal ibandronate sodium injection in public medical institutions in China have grown rapidly in recent years, and it will be close to 1 billion yuan in 2020.
Among them, Hebei Medical University has the largest market share of biology, exceeding 30%, and Chengdu Yuandong Biotechnology Pharmaceuticals followed closely behind, ranking second
.
.
According to data from Menet.
com, the sales of terminal ibandronate sodium injection in public medical institutions in China have grown rapidly in recent years, and it will be close to 1 billion yuan in 2020.
Among them, Hebei Medical University has the largest market share of biology, exceeding 30%, and Chengdu Yuandong Biotechnology Pharmaceuticals followed closely behind, ranking second
.
On August 5, 2021, the information of drug approval documents to be collected is released
Statistics show that ibandronate is injection as early as June 1996, the EU approved by the third-generation bisphosphonate Swiss pharmaceutical company Roche developed for the treatment of malignant tumor hypercalcemia, prevention Bone-related events in patients with breast cancer bone metastases (pathological fractures, bone complications requiring radiotherapy or surgery)
.
Tumor tumor tumor.
Sales of terminal ibandronate sodium injection in public medical institutions in China in recent years (unit: 100 million yuan)
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, in recent years , the sales of terminal ibandronate sodium injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly.
In 2020, it will be close to 1 billion yuan.
Among them, Hebei Medical University has the largest market share of biology, exceeding 30%, followed by Chengdu Yuandong Biopharmaceutical, ranking second
.
Hospital hospital hospitalcom, in recent years , the sales of terminal ibandronate sodium injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly.
In 2020, it will be close to 1 billion yuan.
Among them, Hebei Medical University has the largest market share of biology, exceeding 30%, followed by Chengdu Yuandong Biopharmaceutical, ranking second
.
Status of Supplementary Application for Consistency Evaluation of Ibandronate Sodium Injection
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Ibandronate sodium injection production companies include Chengdu Yuandong Biopharmaceuticals, Qilu Pharmaceuticals, Tianjin Hongri Pharmaceuticals, and Sichuan Meida Kangjiale Pharmaceuticals
.
In March of this year, Chengdu Yuandong Biopharmaceutical won the first review of ibandronate sodium injection.
This time, Qilu Pharmaceutical was approved and became the second company to review the product
.
At present, Ibandronate Sodium Injection and the supplementary application for consistency evaluation of Nanjing Hengsheng Pharmaceutical are under review and approval
.
Enterprise business enterprise.
In March of this year, Chengdu Yuandong Biopharmaceutical won the first review of ibandronate sodium injection.
This time, Qilu Pharmaceutical was approved and became the second company to review the product
.
At present, Ibandronate Sodium Injection and the supplementary application for consistency evaluation of Nanjing Hengsheng Pharmaceutical are under review and approval
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
